FDA grants Kamada orphan drug status for bronchiectasis treatment

NESS ZIONA, Israel The Food and Drug Administration this week granted Kamada orphan drug status to its aerosolized Alpha-1 Antitrypsin, product to treat bronchiectasis, according to publishes reports.

Bronchiectasis is a lung disease that results in the distortion of one or more of the conducting bronchi or airways.

The company stated that the AAT product is currently undergoing Phase II clinical trials.

“This significant recognition grants Kamada various benefits such as research fund support, tax incentives, reduced user fees and seven years of exclusive distribution rights, if the company’s product is first on the U.S. market for this indication,” said chief executive David Tsur in a statement.